Page Arthur B decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,670 shares of the company’s stock after selling 2,141 shares during the quarter. Johnson & Johnson comprises 4.9% of Page Arthur B’s holdings, making the stock its largest holding. Page Arthur B’s holdings in Johnson & Johnson were worth $5,683,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Quadrant Private Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $3,362,000. Delaney Dennis R grew its stake in shares of Johnson & Johnson by 18.7% in the fourth quarter. Delaney Dennis R now owns 24,304 shares of the company’s stock valued at $3,395,000 after buying an additional 3,834 shares in the last quarter. PFG Advisors acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $254,000. Columbus Macro LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $953,000. Finally, Harbour Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $2,955,000. 67.40% of the stock is owned by institutional investors.
A number of equities research analysts have recently weighed in on the company. Deutsche Bank reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, April 18th. Credit Suisse Group dropped their price objective on Johnson & Johnson from $154.00 to $151.00 and set an “outperform” rating for the company in a research note on Friday, April 20th. Jefferies Group set a $153.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, April 13th. Leerink Swann reaffirmed an “outperform” rating and issued a $160.00 price objective (down from $175.00) on shares of Johnson & Johnson in a research note on Wednesday, April 18th. They noted that the move was a valuation call. Finally, Wells Fargo reaffirmed an “outperform” rating and issued a $150.00 price objective (down from $160.00) on shares of Johnson & Johnson in a research note on Wednesday, April 18th. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $142.23.
Shares of Johnson & Johnson opened at $123.85 on Friday, according to Marketbeat. The stock has a market cap of $336.30 billion, a price-to-earnings ratio of 16.97, a price-to-earnings-growth ratio of 1.92 and a beta of 0.74. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a 1 year low of $125.00 and a 1 year high of $125.73.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06. The company had revenue of $20.01 billion during the quarter, compared to the consensus estimate of $19.50 billion. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. Johnson & Johnson’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.83 EPS. equities research analysts expect that Johnson & Johnson will post 8.13 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th will be issued a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a yield of 2.91%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Friday, May 25th. Johnson & Johnson’s payout ratio is 46.03%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.